Medical Devices Startups

Bilihome develops a wearable phototherapy device for treating neonatal jaundice in hospitals and home settings, enabling parents to maintain physical contact with their newborns during treatment. The company provides the device alongside remote monitoring services and implementation support for hospitals to adopt zero-separation care pathways.

1 investor

Bilix develops BRIXELLE-ONCO, a bilirubin nanoparticle technology that serves as a non-toxic drug carrier for anti-cancer agents, designed to reduce side effects in cancer treatment by improving drug delivery to tumor sites. The technology uses naturally occurring bilirubin conjugated with PEG to encapsulate and deliver hydrophobic anti-cancer drugs with minimal systemic toxicity.

1 investor

BioAgilytix provides bioanalytical laboratory services supporting drug development across all phases, from preclinical through clinical studies. The company operates advanced facilities across North America, Europe, and Australia, specializing in large molecule bioanalysis, LC/MS testing, and diagnostic services for the biopharmaceutical industry.

1 investor

BioAlert Solutions develops qPCR-based monitoring systems for detecting Legionella in cooling towers and water systems across North America. The company serves industries, hospitals, and facility managers to enhance public health safety and ensure regulatory compliance.

1 investor

BioAmp Diagnostics develops a chemistry-based rapid diagnostic pipeline (DETECT: Dual-Enzyme Trigger-Enabled Cascade Technology) that delivers infection results in minutes to guide antibiotic prescribing, initially targeting complicated urinary tract infections. The technology is intended to help physicians select the correct antibiotic and support efforts to combat antibiotic resistance.

1 investor

A medical device company developing a non-invasive endoscopic capsule system for gastrointestinal imaging and diagnosis that patients can use at home while physicians monitor results remotely. The company serves gastroenterologists and patients requiring GI tract assessment.

1 investor

Biocare Medical develops automated immunohistochemistry and molecular pathology instrumentation and reagents for tissue diagnostic testing. The company serves clinical and research laboratories, pharmaceutical companies, and biotechnology firms conducting cancer and infectious disease diagnostics.

1 investor

Biocellis develops a patented bioluminescence immunoassay platform that delivers laboratory-grade, picogram-level sensitivity with results in under 60 seconds in a compact, portable format for point-of-care and high-throughput screening. Its diagnostics target human health, veterinary, environmental, food safety, and public screening applications across hospitals, clinics, and field settings.</parameter> <parameter name="founders">[{"full_name": "Vincent Poher", "title": "Co-founder", "linkedin_url": "https://www.linkedin.com/in/vincentpoher/"}, {"full_name": "Thierry Rose", "title": "Co-founder", "linkedin_url": "https://www.linkedin.com/in/thierry-rose-122013254/"}, {"full_name": "Sophie Goyard", "title": "Co-founder", "linkedin_url": "https://www.linkedin.com/in/sophie-goyard-968844103/"}]</parameter> <parameter name="hq_city">Grenoble

1 investor

BioChange develops CellFoam, a biodegradable and biocompatible foam scaffold technology for regenerative medicine that supports tissue repair and organ recovery. Its product lines target dental, aesthetic, and human medical uses as well as veterinary care (including products like ReFoam, Revolette, ReGumVet, VetFoam, and vitaloc), with its veterinary line already in the U.S. market.

1 investor

BioChip Labs provides laboratory testing services for blood disorders, including sickle cell disease and thalassemia, using traditional and proprietary blood cell analysis methods. The company conducts comprehensive biomarker assays and works with clinicians and researchers.

1 investor

BioCircuit Technologies develops advanced medical devices for tissue repair and neuromodulation, with specialization in biomaterials, nitinol design, and bioelectronics. The company serves surgical teams with products like Nerve Tape®, a sutureless device for nerve repair.

1 investor

Biocomposites develops and manufactures calcium-based and medical-grade polymer composite devices used in orthopaedic surgery, including products designed for use in the presence of infection. Founded via a management buyout of a ceramics company, it manufactures around one million units annually and sells to 100 countries.

1 investor

BioConnection is a Contract Development and Manufacturing Organization (CDMO) specializing in filling, finishing, and lyophilizing injectable biopharmaceutical products. The company operates from EMA and US-FDA-approved facilities in Oss, the Netherlands, serving innovative and generic pharmaceutical companies throughout the drug development lifecycle.

1 investor

Biodimension develops tissue engineering and non-animal testing methods including in-vitro platforms, biofabricated tissues, and computational models for pharmaceutical, personal care, and agrochemical industries. The company provides alternatives to animal testing for preclinical research and regenerative medicine applications.

1 investor

Biodol Therapeutics is a biotech company developing proprietary FLT3 inhibitors (BDT compounds) at the preclinical stage to treat neuropathic and chronic pain, including opioid-combination indications. It holds a portfolio of patents covering the use of FLT3 inhibitors for pain treatment.

1 investor

Bioelectrix develops a novel electrical stimulation technology to accelerate wound healing by delivering stable, controlled electrical signals to tissue. The company targets diabetic foot ulcers and other chronic wounds, with initial focus on patients for whom small wounds can become life-threatening complications.

1 investor

Bioelectronica develops hardware and software tools for accelerated antibody discovery using single-cell protein secretion sorting combined with AI-driven sequence analysis. The company serves research institutions and biotech firms in the life sciences industry.

1 investor

Bioemtech provides in vitro cell-based assays and laboratory services for drug discovery and stem cell therapy applications, utilizing cell lines and standardized protocols to measure cytotoxicity, biological activity, and biochemical mechanisms for pharmaceutical research.

1 investor

Biogazelle develops RNA biomarker discovery and transcriptome profiling solutions for clinical research and diagnostics. The company specializes in innovative RNA analysis technologies for medical applications.

1 investor

Biogenera develops BGA002, an anti-tumor therapeutic candidate targeting neuroblastoma and rhabdomyosarcoma, which primarily affect children and adolescents. The company is advancing the drug through clinical development with a structured regulatory pathway in Europe.

1 investor

Biograil is a company backed by venture capital investors specializing in deep tech, sustainable technologies, and life sciences ventures across Europe.

1 investor

Biogroup Fertilité operates a network of fertility and assisted reproduction centers providing in vitro fertilization, artificial insemination, and fertility preservation services to patients across multiple locations. The company emphasizes standardized protocols, safety systems, and scientific innovation in reproductive medicine.

1 investor

Imviva is a clinical-stage biotechnology company developing allogeneic CAR-T cell therapies for oncology and autoimmune diseases. The company focuses on creating safer, more effective off-the-shelf cell therapies designed to improve patient access and outcomes in regenerative medicine.

1 investor

Biointaxis is an academic biotech spin-off developing a gene therapy to restore the function of a defective protein in patients with Friedreich's ataxia, a rare inherited neurodegenerative disease. The company handles early-stage R&D, pre-clinical, and early clinical (Phase I/II) development, aiming to license production and distribution rights to pharmaceutical partners.

1 investor